InDex Pharmaceuticals Holding AB (publ) interim report January – June 2019
Last patient enrolled in the CONDUCT studyPeriod April – June 2019 · Revenues amounted to SEK 0.0 (0.0) million · Operating result amounted to SEK –17.7 (–26.0) million · Result after tax amounted to SEK –17.7 (–26.0) million, corresponding to SEK –0.26 per share (–0.42) before and after dilution · Cash flow from operating activities amounted to SEK –13.9 (–19.7) million Period January – June 2019 · Revenues amounted to SEK 0.0 (0.1) million · Operating result amounted to SEK –34.9 (–44.7) million · Result after tax amounted to SEK –34.9 (–44.7) million,